U.S., Dec. 16 -- ClinicalTrials.gov registry received information related to the study (NCT07282873) titled 'Study of TYK-01054 Capsules in Patients With Advanced Solid Tumors' on Nov. 18.
Brief Summary: This study is to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of the TEAD inhibitor TYK-01054 capsules in patients with locally advanced or metastatic advanced solid tumors
Study Start Date: Jan. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Solid Tumor Malignancies
Malignant Mesothelioma (MM)
Intervention:
DRUG: TYK-01054
capsule
DRUG: TYK-01054
capsule
DRUG: TYK-01054
capsule
Recruitment Status: NOT_YET_RECRUITING
Sponsor: TYK Medicines, Inc
Disclaimer: Curated by HT Syndication....